Free Trial
→ Is it CRAZY to still want reliable profits, despite this market? (From Brownstone Research) (Ad) Buy ARWR Stock  Free ARWR Stock Alerts

Arrowhead Pharmaceuticals (ARWR) Financials

Arrowhead Pharmaceuticals logo
$12.87 +0.53 (+4.29%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$12.87 0.00 (0.00%)
As of 04/15/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Arrowhead Pharmaceuticals

Annual Income Statements for Arrowhead Pharmaceuticals

This table shows Arrowhead Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -59 -92 -82 -34 -54 68 -85 -141 -176 -205 -599
Consolidated Net Income / (Loss)		 -59 -92 -82 -34 -54 68 -85 -141 -176 -209 -610
Net Income / (Loss) Continuing Operations		 -59 -92 -82 -34 -54 68 -85 -141 -176 -209 -610
Total Pre-Tax Income 		-59 -92 -82 -34 -54 68 -85 -141 -173 -206 -612
Total Operating Income		 -53 -96 -82 -37 -56 61 -93 -149 -179 -205 -601
Total Gross Profit		 0.18 0.38 0.16 31 16 169 88 138 243 241 3.55
Total Revenue		 0.18 0.38 0.16 31 16 169 88 138 243 241 3.55
Operating Revenue		 0.18 0.38 0.16 31 16 169 88 138 243 241 3.55
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 53 96 82 68 72 108 181 287 422 446 605
Selling, General & Admin Expense		 19 24 24 17 19 27 52 81 124 93 99
Research & Development Expense		 23 57 62 51 53 81 129 206 297 353 506
Total Other Income / (Expense), net		 -5.44 4.04 0.02 2.62 1.49 6.96 8.61 8.19 5.80 -1.49 -11
Interest Expense		 - - - - - - - 0.00 0.00 18 32
Interest & Investment Income		 0.57 0.73 0.27 0.42 1.05 6.96 9.19 6.12 5.03 15 23
Other Income / (Expense), net		 -5.95 3.31 -0.24 2.20 0.44 0.00 -0.58 2.07 0.77 1.54 -1.75
Income Tax Expense		 0.01 0.00 0.00 0.00 0.00 0.17 0.00 0.00 3.79 2.78 -2.77
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.10 - - - - - 0.00 0.00 -0.43 -4.00 -10
Basic Earnings per Share		 ($1.25) ($1.60) ($1.34) ($0.47) ($0.65) $0.72 ($0.84) ($1.36) ($1.67) ($1.92) ($5.00)
Weighted Average Basic Shares Outstanding		 46.93M 57.36M 61.05M 73.90M 83.64M 93.86M 100.72M 103.75M 105.43M 106.75M 119.78M
Diluted Earnings per Share		 ($1.25) ($1.60) ($1.34) ($0.47) ($0.65) $0.69 ($0.84) ($1.36) ($1.67) ($1.92) ($5.00)
Weighted Average Diluted Shares Outstanding		 46.93M 57.36M 61.05M 73.90M 83.64M 98.61M 100.72M 103.75M 105.43M 106.75M 119.78M
Weighted Average Basic & Diluted Shares Outstanding		 46.93M 57.36M 61.05M 73.90M 83.64M 95.71M 102.76M 104.53M 106.01M 107.43M 124.43M

Quarterly Income Statements for Arrowhead Pharmaceuticals

This table shows Arrowhead Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Net Income / (Loss) Attributable to Common Shareholders		 -72 -86 -41 49 -103 -110 -133 -125 -171 -171 -173
Consolidated Net Income / (Loss)		 -72 -86 -42 48 -104 -111 -135 -127 -174 -173 -175
Net Income / (Loss) Continuing Operations		 -72 -86 -42 48 -104 -111 -135 -127 -174 -173 -175
Total Pre-Tax Income 		-72 -82 -42 48 -103 -109 -139 -127 -174 -173 -175
Total Operating Income		 -73 -84 -42 48 -103 -108 -137 -126 -176 -162 -161
Total Gross Profit		 32 32 63 146 16 16 3.55 0.00 0.00 - 2.50
Total Revenue		 32 32 63 146 16 16 3.55 0.00 0.00 - 2.50
Operating Revenue		 32 32 63 146 16 16 3.55 0.00 0.00 - 2.50
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 105 115 105 98 119 124 140 126 176 162 164
Selling, General & Admin Expense		 33 32 21 23 24 25 24 25 24 26 27
Research & Development Expense		 72 83 84 75 95 100 116 101 152 136 137
Total Other Income / (Expense), net		 0.86 1.67 0.34 -0.49 -0.68 -0.66 -2.14 -0.81 2.16 -11 -14
Interest Expense		 0.00 - 2.85 5.06 5.16 5.26 5.37 7.24 5.09 15 22
Interest & Investment Income		 1.24 1.58 2.68 4.56 4.17 3.89 2.80 6.25 6.50 7.17 7.60
Other Income / (Expense), net		 -0.38 0.09 0.51 0.01 0.31 0.72 0.42 0.19 0.76 -3.12 0.34
Income Tax Expense		 0.00 3.79 0.00 0.00 0.74 2.04 -3.31 0.00 0.00 0.55 0.10
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 -0.43 -0.49 -1.00 -1.18 -1.34 -2.51 -1.70 -3.18 -2.81 -2.13
Basic Earnings per Share		 ($0.68) ($0.81) ($0.39) $0.46 ($0.96) ($1.03) ($1.24) ($1.02) ($1.38) ($1.36) ($1.39)
Weighted Average Basic Shares Outstanding		 105.75M 105.43M 106.04M 106.76M 107.00M 106.75M 107.42M 123.29M 124.20M 119.78M 124.85M
Diluted Earnings per Share		 ($0.68) ($0.80) ($0.39) $0.45 ($0.96) ($1.02) ($1.24) ($1.02) ($1.38) ($1.36) ($1.39)
Weighted Average Diluted Shares Outstanding		 105.75M 105.43M 106.04M 108.14M 107.00M 106.75M 107.42M 123.29M 124.20M 119.78M 124.85M
Weighted Average Basic & Diluted Shares Outstanding		 105.85M 106.01M 108.31M 106.90M 107.19M 107.43M 123.90M 124.20M 124.32M 124.43M 126.10M

Annual Cash Flow Statements for Arrowhead Pharmaceuticals

This table details how cash moves in and out of Arrowhead Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 113 -51 4.15 -61 5.29 192 -79 41 -76 3.01 -12
Net Cash From Operating Activities		 -35 -66 -64 -24 -47 173 -96 171 -136 -154 -463
Net Cash From Continuing Operating Activities		 -35 -66 -64 -24 -47 173 -96 171 -136 -154 -463
Net Income / (Loss) Continuing Operations		 -59 -92 -82 -34 -54 68 -85 -141 -176 -209 -610
Consolidated Net Income / (Loss)		 -59 -92 -82 -34 -54 68 -85 -141 -176 -209 -610
Depreciation Expense		 1.35 2.34 3.26 4.69 4.70 4.44 5.94 8.27 10 12 19
Amortization Expense		 0.79 1.11 0.23 -0.04 0.38 1.07 0.53 0.27 2.91 -2.02 -3.24
Non-Cash Adjustments To Reconcile Net Income		 7.84 20 14 7.89 8.45 12 44 78 139 143 109
Changes in Operating Assets and Liabilities, net		 13 2.43 0.16 -2.10 -6.31 87 -62 225 -112 -98 23
Net Cash From Investing Activities		 -36 14 13 -49 -7.43 -48 -241 -142 -5.42 -96 -420
Net Cash From Continuing Investing Activities		 -36 14 13 -49 -7.43 -48 -241 -142 -5.42 -96 -420
Purchase of Property, Plant & Equipment		 -1.72 -12 -3.86 -7.92 -1.42 -12 -12 -24 -53 -177 -141
Purchase of Investments		 -46 0.00 0.00 -45 -52 -90 -279 -241 -223 -246 -721
Sale and/or Maturity of Investments		 12 26 17 4.25 46 55 50 123 271 327 442
Net Cash From Financing Activities		 185 0.29 55 12 60 66 258 11 65 253 871
Net Cash From Continuing Financing Activities		 185 0.29 55 12 60 66 258 11 65 253 871
Repayment of Debt		 -0.23 -0.21 -0.22 -0.20 -0.21 -2.42 - - 0.00 0.00 -3.13
Issuance of Debt		 - - - - - - - - 0.00 0.00 392
Issuance of Common Equity		 173 0.00 52 12 57 61 250 - 0.00 0.00 429
Other Financing Activities, net		 13 0.50 3.12 -0.17 3.58 8.28 7.47 11 65 253 52
Cash Income Taxes Paid		 0.01 0.00 0.00 0.00 -0.00 -0.30 0.10 -0.00 -0.00 0.00 -3.74

Quarterly Cash Flow Statements for Arrowhead Pharmaceuticals

This table details how cash moves in and out of Arrowhead Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Net Change in Cash & Equivalents		 53 -31 94 -67 -30 5.40 -53 69 -58 29 -49
Net Cash From Operating Activities		 -69 -69 -76 -32 -21 -26 -118 -92 -115 -137 -146
Net Cash From Continuing Operating Activities		 -69 -69 -76 -32 -21 -26 -118 -92 -115 -137 -146
Net Income / (Loss) Continuing Operations		 -72 -86 -42 48 -104 -111 -135 -127 -174 -173 -175
Consolidated Net Income / (Loss)		 -72 -86 -42 48 -104 -111 -135 -127 -174 -173 -175
Depreciation Expense		 2.59 2.66 2.69 2.67 3.28 3.86 4.26 4.53 4.78 5.03 5.24
Amortization Expense		 1.68 0.90 0.69 -0.77 -0.95 -0.99 -0.84 1.73 6.99 -11 -5.70
Non-Cash Adjustments To Reconcile Net Income		 39 41 23 26 26 68 29 26 22 33 36
Changes in Operating Assets and Liabilities, net		 -40 -28 -60 -108 55 14 -15 2.75 25 9.59 -6.31
Net Cash From Investing Activities		 61 36 -81 -36 -9.91 31 65 -269 6.95 -223 77
Net Cash From Continuing Investing Activities		 61 36 -81 -36 -9.91 31 65 -269 6.95 -223 77
Purchase of Property, Plant & Equipment		 -9.54 -33 -39 -27 -47 -64 -69 -34 -14 -24 -7.52
Purchase of Investments		 -75 - -111 -81 -41 -12 0.00 -310 -119 -292 -34
Sale and/or Maturity of Investments		 146 69 69 73 78 107 133 75 140 94 118
Net Cash From Financing Activities		 61 0.86 251 0.52 1.14 0.82 0.27 431 50 389 21
Net Cash From Continuing Financing Activities		 61 0.86 251 0.52 1.14 0.82 0.27 431 50 389 21
Repayment of Debt		 - - - - - - 0.00 - - - -5.00
Issuance of Common Equity		 - - - - - - 0.00 - - - 25
Other Financing Activities, net		 61 0.86 251 0.52 1.14 0.82 0.27 1.51 50 0.22 0.63
Cash Income Taxes Paid		 - -0.00 0.00 - - - -1.00 -2.02 -0.05 -0.68 -0.01

Annual Balance Sheets for Arrowhead Pharmaceuticals

This table presents Arrowhead Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 183 132 128 104 112 350 523 710 692 766 1,140
Total Current Assets		 155 103 91 68 79 265 322 385 405 416 695
Cash & Equivalents		 133 81 85 25 30 222 144 184 108 111 103
Short-Term Investments		 22 18 0.00 41 46 37 172 183 268 293 578
Accounts Receivable		 - 0.00 0.08 0.07 0.33 0.66 0.85 10 1.41 - 0.00
Prepaid Expenses		 0.59 3.29 1.29 0.87 1.27 3.32 4.25 4.36 7.29 8.81 9.54
Other Current Assets		 0.05 0.82 3.77 1.36 0.64 2.56 1.78 2.19 20 4.03 4.97
Plant, Property, & Equipment, net		 3.87 4.53 15 16 14 23 31 49 110 290 386
Total Noncurrent Assets		 24 25 22 21 19 61 169 277 176 59 58
Intangible Assets		 1.01 25 22 20 19 17 15 14 12 10 8.56
Other Noncurrent Operating Assets		 0.04 0.05 0.12 0.14 0.14 0.14 16 18 59 49 50
Total Liabilities & Shareholders' Equity		 183 132 128 104 112 350 523 710 692 766 1,140
Total Liabilities		 17 23 33 23 16 106 61 301 274 478 949
Total Current Liabilities		 12 16 26 19 12 97 41 147 139 105 103
Short-Term Debt		 0.26 0.22 0.19 0.21 0.22 - - - - - 0.00
Accounts Payable		 2.58 5.03 12 4.08 2.81 7.65 6.83 9.46 2.87 36 11
Accrued Expenses		 1.40 5.38 4.59 4.56 5.04 6.50 5.39 14 47 40 63
Current Employee Benefit Liabilities		 3.27 3.82 3.97 3.40 3.94 4.96 8.06 9.77 12 18 22
Other Current Liabilities		 4.23 1.35 1.65 0.74 0.05 0.02 1.11 2.25 2.78 11 6.77
Total Noncurrent Liabilities		 4.98 6.75 7.51 4.45 4.00 8.74 20 155 135 373 846
Long-Term Debt		 - 0.00 2.53 2.33 2.10 - - - - 0.00 393
Capital Lease Obligations		 0.76 0.54 - - - - - - - 105 111
Other Noncurrent Operating Liabilities		 4.23 6.06 0.20 0.20 0.20 0.00 20 23 79 268 341
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 166 110 95 81 95 244 462 409 418 287 191
Total Preferred & Common Equity		 167 110 96 81 96 245 462 409 399 271 185
Total Common Equity		 167 110 96 81 96 245 462 409 399 271 185
Common Stock		 391 427 494 514 583 664 966 1,054 1,219 1,301 1,806
Retained Earnings		 -225 -317 -398 -433 -487 -419 -504 -645 -821 -1,026 -1,626
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.14 0.01 0.03 -0.02 -0.39 0.02 -0.07 -0.14 -3.22 4.75
Noncontrolling Interest		 -0.56 -0.56 -0.56 -0.56 -0.56 -0.56 - 0.00 20 16 5.62

Quarterly Balance Sheets for Arrowhead Pharmaceuticals

This table presents Arrowhead Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Total Assets		 752 891 891 796 626 955 884 1,014
Total Current Assets		 432 575 575 470 238 542 450 571
Cash & Equivalents		 139 202 135 105 58 128 69 54
Short-Term Investments		 277 300 346 346 162 395 367 499
Accounts Receivable		 0.24 40 69 1.25 - - - 2.50
Prepaid Expenses		 6.76 8.41 9.94 10 11 11 9.21 9.37
Other Current Assets		 8.89 25 14 7.16 7.10 7.51 4.18 5.74
Plant, Property, & Equipment, net		 72 147 185 231 333 359 376 387
Total Noncurrent Assets		 247 169 131 94 55 54 58 56
Intangible Assets		 12 12 11 11 9.84 9.41 8.99 8.14
Other Noncurrent Operating Assets		 69 42 41 41 45 45 49 48
Total Liabilities & Shareholders' Equity		 752 891 891 796 626 955 884 1,014
Total Liabilities		 278 495 426 414 453 460 545 958
Total Current Liabilities		 128 122 87 70 64 65 97 94
Short-Term Debt		 - - - - - - - 1.63
Accounts Payable		 5.89 0.80 9.56 7.87 4.46 8.52 27 14
Accrued Expenses		 32 48 40 38 47 37 48 59
Current Employee Benefit Liabilities		 2.65 4.09 5.49 4.43 8.78 14 16 11
Other Current Liabilities		 2.88 2.66 2.71 2.82 3.88 5.86 6.47 7.00
Total Noncurrent Liabilities		 149 373 339 344 389 395 448 864
Long-Term Debt		 - - - - - - - 408
Capital Lease Obligations		 - 79 80 80 115 114 112 109
Other Noncurrent Operating Liabilities		 78 253 258 264 274 281 336 347
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 474 396 465 382 174 495 339 56
Total Preferred & Common Equity		 454 377 447 365 160 484 331 53
Total Common Equity		 454 377 447 365 160 484 331 53
Common Stock		 1,189 1,239 1,261 1,282 1,321 1,769 1,787 1,847
Retained Earnings		 -735 -862 -813 -916 -1,159 -1,284 -1,455 -1,799
Accumulated Other Comprehensive Income / (Loss)		 -0.14 -0.26 -0.33 -0.41 -1.26 -1.10 -0.99 4.14
Noncontrolling Interest		 20 19 18 17 13 12 8.43 3.49

Annual Metrics and Ratios for Arrowhead Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Arrowhead Pharmaceuticals' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -39.71% 118.29% -58.55% 19,736.49% -48.60% 945.67% -47.87% 57.16% 75.89% -1.03% -98.52%
EBITDA Growth		 -96.29% -56.29% 12.02% 61.59% -67.23% 232.30% -230.85% -58.62% -18.77% -17.38% -204.41%
EBIT Growth		 -91.28% -56.46% 11.53% 57.56% -59.51% 210.26% -253.20% -56.78% -20.94% -14.47% -196.28%
NOPAT Growth		 -116.66% -80.14% 14.83% 54.74% -51.20% 255.88% -206.84% -59.98% -19.77% -14.84% -193.21%
Net Income Growth		 -85.23% -56.56% 11.11% 57.93% -58.38% 224.84% -224.39% -66.58% -25.31% -18.57% -191.34%
EPS Growth		 3.85% -28.00% 16.25% 64.93% -38.30% 206.15% -221.74% -61.90% -22.79% -14.97% -160.42%
Operating Cash Flow Growth		 -86.08% -85.53% 1.95% 62.84% -97.27% 466.42% -155.37% 278.82% -179.46% -13.05% -200.77%
Free Cash Flow Firm Growth		 -277.58% -208.60% 34.89% 46.01% -35.43% 432.37% -194.28% 182.07% -343.58% 26.36% -128.52%
Invested Capital Growth		 -466.60% 213.48% 6.54% 43.66% 18.21% -379.77% 114.95% -2,424.83% 68.75% 81.45% 220.72%
Revenue Q/Q Growth		 0.00% 0.00% -7.32% 38.21% 18.68% 23.43% -28.84% 28.48% -2.68% -6.04% -81.93%
EBITDA Q/Q Growth		 -18.48% -2.15% 3.03% 28.08% -1.01% 46.75% -221.92% -10.22% -12.52% -14.58% -12.80%
EBIT Q/Q Growth		 -18.17% -2.49% 3.08% 24.67% -0.51% 51.52% -180.66% -10.38% -12.13% -13.29% -10.59%
NOPAT Q/Q Growth		 -36.88% -3.09% 4.04% 23.78% -1.67% 51.15% -178.91% -10.99% -11.88% -13.57% -9.85%
Net Income Q/Q Growth		 -17.22% -2.58% 3.00% 25.05% -0.05% 49.37% -246.32% -11.87% -14.66% -13.61% -11.39%
EPS Q/Q Growth		 -30.21% 1.84% 4.29% 29.85% 5.80% 46.81% -236.00% -10.57% -12.84% -12.94% -7.30%
Operating Cash Flow Q/Q Growth		 -18.49% -1.70% 2.77% 3.92% 12.14% 10.53% -35.44% -6.94% -48.90% 21.76% -31.66%
Free Cash Flow Firm Q/Q Growth		 -24.79% -2.72% -0.33% 4.75% 10.76% 3.50% -9.63% -23.12% -25.72% 3.19% -3.95%
Invested Capital Q/Q Growth		 -545.95% -41.69% -31.58% 4.74% -19.06% 15.68% -68.60% 1.56% 40.94% 63.59% -0.22%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -32,621.89% -23,356.26% -49,575.55% -95.98% -312.31% 39.51% -99.19% -100.11% -67.59% -80.17% -16,543.99%
Operating Margin		 -30,443.59% -25,124.08% -51,627.09% -117.79% -346.52% 36.25% -105.87% -107.77% -73.39% -85.16% -16,927.06%
EBIT Margin		 -33,844.49% -24,258.54% -51,780.99% -110.78% -343.80% 36.25% -106.53% -106.28% -73.08% -84.52% -16,976.29%
Profit (Net Income) Margin		 -33,557.38% -24,068.29% -51,614.64% -109.46% -337.32% 40.27% -96.09% -101.85% -72.56% -86.93% -17,169.61%
Tax Burden Percent		 100.01% 100.00% 100.00% 100.01% 100.00% 99.74% 100.00% 100.00% 102.19% 101.35% 99.55%
Interest Burden Percent		 99.14% 99.21% 99.68% 98.81% 98.11% 111.37% 90.20% 95.84% 97.17% 101.49% 101.60%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.26% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -9,727.21% -476.61% -171.63% -201.70% 0.00% 0.00% 0.00% 0.00% 0.00% -34,263.52%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -9,709.16% -449.48% -159.98% -179.42% 0.00% 0.00% 0.00% 0.00% 0.00% -34,184.09%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 9,660.50% 396.74% 132.54% 139.86% 0.00% 0.00% 0.00% 0.00% 0.00% 34,008.54%
Return on Equity (ROE)		 -61.26% -66.72% -79.87% -39.09% -61.84% 40.07% -23.96% -32.36% -42.67% -59.33% -254.98%
Cash Return on Invested Capital (CROIC)		 0.00% -765.99% -482.94% -207.46% -218.39% 0.00% -1,509.88% 0.00% 0.00% 0.00% -3,122.72%
Operating Return on Assets (OROA)		 -53.81% -58.82% -62.96% -29.97% -51.47% 26.52% -21.49% -23.85% -25.35% -27.92% -63.28%
Return on Assets (ROA)		 -53.35% -58.36% -62.76% -29.61% -50.50% 29.46% -19.39% -22.85% -25.18% -28.72% -64.00%
Return on Common Equity (ROCE)		 -62.00% -66.99% -80.30% -39.34% -62.23% 40.20% -23.98% -32.36% -41.65% -56.33% -243.55%
Return on Equity Simple (ROE_SIMPLE)		 -35.26% -83.45% -85.50% -42.22% -56.84% 27.79% -18.31% -34.45% -44.29% -77.13% -328.77%
Net Operating Profit after Tax (NOPAT)		 -37 -67 -57 -26 -39 61 -65 -104 -125 -144 -421
NOPAT Margin		 -21,310.51% -17,586.85% -36,138.97% -82.45% -242.56% 36.16% -74.11% -75.44% -51.37% -59.61% -11,848.94%
Net Nonoperating Expense Percent (NNEP)		 -21.04% -18.06% -27.13% -11.64% -22.28% 3.68% -5.12% -6.85% -9.41% -16.84% -79.42%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 10,699.06% 6,409.74% 14,902.07% 55.72% 118.38% 15.73% 59.41% 58.56% 51.16% 38.44% 2,781.22%
R&D to Revenue		 13,221.74% 15,028.83% 39,232.39% 162.08% 328.13% 48.02% 146.46% 149.21% 122.23% 146.71% 14,245.85%
Operating Expenses to Revenue		 30,543.59% 25,224.08% 51,727.09% 217.79% 446.52% 63.75% 205.87% 207.77% 173.39% 185.16% 17,027.06%
Earnings before Interest and Taxes (EBIT)		 -59 -93 -82 -35 -55 61 -94 -147 -178 -203 -603
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -57 -89 -78 -30 -50 67 -87 -138 -164 -193 -587
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.69 3.11 4.67 3.98 17.61 10.98 9.54 15.92 8.78 10.61 12.99
Price to Tangible Book Value (P/TBV)		 4.72 4.02 6.08 5.31 21.91 11.80 9.87 16.47 9.05 11.03 13.61
Price to Revenue (P/Rev)		 4,465.48 897.19 2,820.10 10.31 104.53 15.91 50.06 47.07 14.38 11.96 678.12
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 39.51 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 2.53% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 21.00 29.33 14.62 76.67 0.00 449.11 0.00 0.00 0.00 156.29
Enterprise Value to Revenue (EV/Rev)		 3,455.28 639.20 2,294.66 8.28 99.90 14.11 44.91 42.63 12.48 10.79 629.92
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 35.71 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 38.93 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 39.03 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 13.77 0.00 34.41 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 16.91 0.00 54.07 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.01 0.03 0.03 0.02 0.00 0.00 0.00 0.00 0.36 2.64
Long-Term Debt to Equity		 0.00 0.00 0.03 0.03 0.02 0.00 0.00 0.00 0.00 0.36 2.64
Financial Leverage		 -1.06 -1.00 -0.88 -0.83 -0.78 -1.11 -1.07 -1.22 -1.32 -1.11 -0.99
Leverage Ratio		 1.15 1.14 1.27 1.32 1.22 1.36 1.24 1.42 1.70 2.07 3.98
Compound Leverage Factor		 1.14 1.13 1.27 1.30 1.20 1.51 1.11 1.36 1.65 2.10 4.05
Debt to Total Capital		 0.61% 0.69% 2.79% 3.04% 2.38% 0.00% 0.00% 0.00% 0.00% 26.70% 72.52%
Short-Term Debt to Total Capital		 0.16% 0.20% 0.20% 0.25% 0.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.45% 0.49% 2.59% 2.79% 2.15% 0.00% 0.00% 0.00% 0.00% 26.70% 72.52%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.33% -0.50% -0.57% -0.67% -0.57% -0.23% 0.00% 0.00% 4.74% 4.04% 0.81%
Common Equity to Total Capital		 99.72% 99.82% 97.78% 97.63% 98.19% 100.23% 100.00% 100.00% 95.26% 69.26% 26.67%
Debt to EBITDA		 -0.02 -0.01 -0.03 -0.08 -0.05 0.00 0.00 0.00 0.00 -0.54 -0.86
Net Debt to EBITDA		 3.09 1.10 1.05 2.09 1.47 0.00 0.00 0.00 0.00 1.55 0.30
Long-Term Debt to EBITDA		 -0.01 -0.01 -0.03 -0.08 -0.04 0.00 0.00 0.00 0.00 -0.54 -0.86
Debt to NOPAT		 -0.03 -0.01 -0.05 -0.10 -0.06 0.00 0.00 0.00 0.00 -0.73 -1.20
Net Debt to NOPAT		 4.73 1.46 1.44 2.44 1.90 0.00 0.00 0.00 0.00 2.08 0.42
Long-Term Debt to NOPAT		 -0.02 -0.01 -0.04 -0.09 -0.05 0.00 0.00 0.00 0.00 -0.73 -1.20
Altman Z-Score		 26.01 4.21 2.23 2.33 54.96 15.19 42.39 11.60 5.98 1.66 -1.59
Noncontrolling Interest Sharing Ratio		 -1.21% -0.40% -0.54% -0.63% -0.63% -0.33% -0.08% 0.00% 2.40% 5.05% 4.48%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.07 6.47 3.53 3.63 6.37 2.73 7.92 2.62 2.92 3.95 6.74
Quick Ratio		 13.01 6.21 3.33 3.51 6.22 2.67 7.78 2.58 2.72 3.83 6.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -89 -58 -31 -42 141 -133 109 -266 -196 -447
Operating Cash Flow to CapEx		 -2,074.33% -548.93% -1,669.00% -302.33% -3,322.66% 1,441.84% -801.55% 726.91% -257.94% -87.07% -327.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.67 -13.81
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.40 -14.31
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -18.04 -18.68
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.27 0.15 0.73 0.20 0.22 0.35 0.33 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 439.89 81.70 341.44 116.75 24.91 41.70 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.05 0.09 0.02 2.03 1.10 9.09 3.25 3.48 3.06 1.20 0.01
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.83 4.47 1.07 3.13 14.65 8.75 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.83 4.47 1.07 3.13 14.65 8.75 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -10 12 12 18 21 -59 8.80 -205 -64 -12 14
Invested Capital Turnover		 -0.03 0.55 0.01 2.08 0.83 -8.93 -3.52 -1.41 -1.81 -6.35 2.89
Increase / (Decrease) in Invested Capital		 -8.44 22 0.76 5.41 3.24 -80 68 -213 141 52 26
Enterprise Value (EV)		 605 244 363 260 1,613 2,382 3,952 5,896 3,036 2,597 2,237
Market Capitalization		 781 343 447 324 1,687 2,686 4,405 6,509 3,498 2,880 2,408
Book Value per Share		 $3.15 $1.85 $1.57 $1.09 $1.09 $2.57 $4.51 $3.92 $3.77 $2.53 $1.49
Tangible Book Value per Share		 $3.13 $1.43 $1.21 $0.82 $0.88 $2.39 $4.36 $3.79 $3.65 $2.44 $1.42
Total Capital		 167 110 98 83 98 244 462 409 418 392 695
Total Debt		 1.02 0.76 2.73 2.53 2.33 0.00 0.00 0.00 0.00 105 504
Total Long-Term Debt		 0.76 0.54 2.53 2.33 2.10 0.00 0.00 0.00 0.00 105 504
Net Debt		 -176 -98 -83 -63 -74 -303 -453 -613 -482 -299 -177
Capital Expenditures (CapEx)		 1.71 12 3.86 7.92 1.42 12 12 24 53 177 141
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -12 -20 -16 -9.91 -91 -34 -130 -110 -93 -89
Debt-free Net Working Capital (DFNWC)		 143 87 65 49 67 168 282 238 266 311 592
Net Working Capital (NWC)		 143 87 65 49 66 168 282 238 266 311 592
Net Nonoperating Expense (NNE)		 21 25 25 8.48 15 -6.94 19 37 52 66 189
Net Nonoperating Obligations (NNO)		 -176 -98 -83 -63 -74 -303 -453 -613 -482 -299 -177
Total Depreciation and Amortization (D&A)		 2.14 3.45 3.49 4.65 5.08 5.51 6.47 8.53 13 10 15
Debt-free, Cash-free Net Working Capital to Revenue		 -6,254.80% -3,027.78% -12,829.54% -51.57% -61.37% -53.63% -38.42% -93.81% -45.20% -38.47% -2,496.71%
Debt-free Net Working Capital to Revenue		 81,838.71% 22,824.12% 41,086.23% 157.32% 412.75% 99.63% 320.13% 172.15% 109.55% 129.19% 16,679.89%
Net Working Capital to Revenue		 81,687.85% 22,767.17% 40,963.51% 156.66% 411.36% 99.63% 320.13% 172.15% 109.55% 129.19% 16,679.89%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.25) ($1.60) ($1.34) ($0.47) ($0.65) $0.72 ($0.84) ($1.36) ($1.67) ($1.92) ($5.00)
Adjusted Weighted Average Basic Shares Outstanding		 54.68M 59.55M 74.17M 74.83M 92.22M 93.86M 100.72M 103.75M 105.43M 106.75M 119.78M
Adjusted Diluted Earnings per Share		 ($1.25) ($1.60) ($1.34) ($0.47) ($0.65) $0.69 ($0.84) ($1.36) ($1.67) ($1.92) ($5.00)
Adjusted Weighted Average Diluted Shares Outstanding		 54.68M 59.55M 74.17M 74.83M 92.22M 98.61M 100.72M 103.75M 105.43M 106.75M 119.78M
Adjusted Basic & Diluted Earnings per Share		 ($1.25) ($1.60) ($1.34) ($0.47) ($0.65) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 46.93M 57.36M 61.05M 73.90M 83.64M 95.71M 102.76M 104.53M 106.01M 107.43M 124.43M
Normalized Net Operating Profit after Tax (NOPAT)		 -34 -66 -60 -26 -39 61 -65 -104 -125 -144 -421
Normalized NOPAT Margin		 -19,467.75% -17,240.24% -37,824.12% -82.45% -242.56% 36.16% -74.11% -75.44% -51.37% -59.61% -11,848.94%
Pre Tax Income Margin		 -33,554.35% -24,067.67% -51,613.12% -109.46% -337.30% 40.37% -96.09% -101.85% -71.01% -85.78% -17,247.54%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.10 -18.63
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.83 -13.01
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -20.75 -23.01
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -17.47 -17.38
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Arrowhead Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Arrowhead Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -29.37% -17.52% 127.95% -3.65% -51.18% -49.02% -94.32% -100.00% -100.00% 0.00% -29.60%
EBITDA Growth		 -135.86% -29.56% 38.04% 7.64% -45.01% -30.63% -246.94% -339.16% -63.50% -63.67% -21.74%
EBIT Growth		 -134.86% -29.79% 34.99% 11.22% -39.72% -28.51% -227.01% -361.56% -71.28% -53.63% -18.33%
NOPAT Growth		 -128.78% -29.20% 33.46% 15.91% -40.86% -29.23% -224.07% -283.40% -71.51% -49.73% -18.21%
Net Income Growth		 -140.76% -35.61% 33.50% 7.46% -44.53% -29.17% -223.78% -366.37% -67.08% -56.14% -29.43%
EPS Growth		 -134.48% -31.15% 35.00% 9.76% -41.18% -27.50% -217.95% -326.67% -43.75% -33.33% -12.10%
Operating Cash Flow Growth		 -132.40% -186.06% -23.17% -150.49% 69.81% 62.28% -56.05% -191.68% -455.51% -429.26% -24.13%
Free Cash Flow Firm Growth		 -170.53% -218.68% -137.18% -533.22% 2.01% 35.83% -386.57% -113.73% -15.34% -9.23% 78.35%
Invested Capital Growth		 47.91% 68.75% 19.06% 90.30% 69.91% 81.45% 148.39% 685.99% 144.04% 220.72% -68.15%
Revenue Q/Q Growth		 -78.65% -2.58% 98.09% 133.86% -89.18% 1.72% -77.94% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -248.36% -16.19% 52.30% 230.91% -299.86% -4.67% -26.69% 9.76% -36.63% -4.78% 5.77%
EBIT Q/Q Growth		 -269.20% -14.26% 50.29% 215.73% -312.56% -5.09% -26.49% 7.44% -39.19% 5.74% 2.57%
NOPAT Q/Q Growth		 -222.82% -14.98% 49.74% 263.31% -249.26% -5.48% -26.05% 7.58% -39.58% 7.91% 0.49%
Net Income Q/Q Growth		 -262.39% -19.29% 51.35% 214.03% -318.40% -6.62% -21.94% 6.19% -36.99% 0.36% -1.08%
EPS Q/Q Growth		 -265.85% -17.65% 51.25% 215.38% -313.33% -6.25% -21.57% 17.74% -35.29% 1.45% -2.21%
Operating Cash Flow Q/Q Growth		 -209.70% 0.11% -9.86% 58.06% 34.40% -24.78% -354.52% 21.61% -24.94% -18.89% -6.60%
Free Cash Flow Firm Q/Q Growth		 -978.84% -32.35% 68.45% -40.58% -66.95% 13.32% -139.19% 38.25% 9.91% 17.92% 52.58%
Invested Capital Q/Q Growth		 28.42% 40.94% -121.75% 89.66% -122.09% 63.59% 678.54% 25.27% -83.31% -0.22% 52.67%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 -212.91% -253.94% -61.15% 34.23% -632.35% -650.69% -3,736.86% 0.00% 0.00% 0.00% -6,461.60%
Operating Margin		 -224.94% -265.49% -67.36% 32.93% -648.99% -672.98% -3,845.25% 0.00% 0.00% 0.00% -6,456.48%
EBIT Margin		 -226.11% -265.21% -66.55% 32.94% -647.06% -668.53% -3,833.40% 0.00% 0.00% 0.00% -6,442.84%
Profit (Net Income) Margin		 -222.28% -272.18% -66.85% 32.60% -657.98% -689.66% -3,812.33% 0.00% 0.00% 0.00% -7,008.72%
Tax Burden Percent		 100.00% 104.61% 100.04% 100.00% 100.72% 101.86% 97.61% 100.00% 100.00% 100.32% 100.06%
Interest Burden Percent		 98.31% 98.11% 100.40% 98.97% 100.96% 101.28% 101.88% 100.79% 99.20% 104.52% 108.72%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -249.86%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -160.54%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 97.35%
Return on Equity (ROE)		 -33.79% -42.67% -40.43% -33.17% -43.03% -59.33% -106.24% 0.00% -151.84% 0.00% -152.50%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -612.23% -503.04% -2,997.65% -3,122.72% -865.57%
Operating Return on Assets (OROA)		 -76.02% -92.02% -24.21% 11.27% -214.24% -220.84% -918.03% 0.00% 0.00% 0.00% -19.64%
Return on Assets (ROA)		 -74.74% -94.44% -24.32% 11.15% -217.86% -227.82% -912.99% 0.00% 0.00% 0.00% -21.37%
Return on Common Equity (ROCE)		 -33.04% -41.65% -39.41% -32.50% -41.15% -56.33% -100.16% 0.00% -146.46% 0.00% -141.36%
Return on Equity Simple (ROE_SIMPLE)		 -33.91% 0.00% -41.22% -34.05% -50.49% 0.00% -188.79% -98.70% -165.59% 0.00% -1,235.12%
Net Operating Profit after Tax (NOPAT)		 -51 -59 -29 48 -72 -76 -96 -88 -123 -114 -113
NOPAT Margin		 -157.46% -185.85% -47.16% 32.93% -454.29% -471.09% -2,691.68% 0.00% 0.00% 0.00% -4,519.54%
Net Nonoperating Expense Percent (NNEP)		 -3.42% -4.98% -2.27% -0.09% -6.47% -9.01% -12.37% -8.70% -13.71% -25.14% -89.32%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -33.09% - - - -19.66%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 102.25% 101.43% 33.55% 15.88% 150.21% 152.65% 664.74% 0.00% 0.00% 0.00% 1,076.40%
R&D to Revenue		 222.70% 264.06% 133.81% 51.19% 598.78% 620.33% 3,280.51% 0.00% 0.00% 0.00% 5,480.08%
Operating Expenses to Revenue		 324.94% 365.49% 167.36% 67.07% 748.99% 772.98% 3,945.25% 0.00% 0.00% 0.00% 6,556.48%
Earnings before Interest and Taxes (EBIT)		 -73 -84 -42 48 -102 -108 -136 -126 -175 -165 -161
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -69 -80 -38 50 -100 -105 -133 -120 -164 -171 -162
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 8.20 8.78 11.40 6.16 10.45 10.61 20.45 7.32 9.77 12.99 44.48
Price to Tangible Book Value (P/TBV)		 8.43 9.05 11.76 6.31 10.76 11.03 21.78 7.47 10.04 13.61 52.63
Price to Revenue (P/Rev)		 14.90 14.38 15.45 10.08 14.88 11.96 18.05 99.89 164.29 678.12 935.75
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 46.48 36.61 203.01 156.29 105.66
Enterprise Value to Revenue (EV/Rev)		 12.65 12.48 13.58 8.39 13.33 10.79 17.54 88.68 148.20 629.92 923.45
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.20 0.17 0.21 0.36 0.66 0.23 0.33 2.64 9.25
Long-Term Debt to Equity		 0.00 0.00 0.20 0.17 0.21 0.36 0.66 0.23 0.33 2.64 9.22
Financial Leverage		 -1.35 -1.32 -1.41 -1.18 -1.16 -1.11 -1.13 -0.93 -1.03 -0.99 -0.61
Leverage Ratio		 1.63 1.70 1.99 1.74 1.81 2.07 2.66 1.92 2.33 3.98 7.14
Compound Leverage Factor		 1.60 1.66 2.00 1.72 1.83 2.09 2.71 1.94 2.31 4.16 7.76
Debt to Total Capital		 0.00% 0.00% 16.70% 14.69% 17.30% 26.70% 39.86% 18.66% 24.84% 72.52% 90.24%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.28%
Long-Term Debt to Total Capital		 0.00% 0.00% 16.70% 14.69% 17.30% 26.70% 39.86% 18.66% 24.84% 72.52% 89.96%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 4.27% 4.74% 4.06% 3.36% 3.71% 4.04% 4.61% 1.91% 1.87% 0.81% 0.61%
Common Equity to Total Capital		 95.73% 95.26% 79.24% 81.95% 78.99% 69.26% 55.53% 79.44% 73.29% 26.67% 9.15%
Debt to EBITDA		 0.00 0.00 -0.56 -0.58 -0.47 -0.54 -0.40 -0.25 -0.22 -0.86 -0.84
Net Debt to EBITDA		 0.00 0.00 3.82 3.49 2.46 1.55 0.37 0.90 0.62 0.30 0.06
Long-Term Debt to EBITDA		 0.00 0.00 -0.56 -0.58 -0.47 -0.54 -0.40 -0.25 -0.22 -0.86 -0.84
Debt to NOPAT		 0.00 0.00 -0.72 -0.76 -0.63 -0.73 -0.55 -0.34 -0.29 -1.20 -1.18
Net Debt to NOPAT		 0.00 0.00 4.89 4.55 3.28 2.08 0.50 1.23 0.85 0.42 0.08
Long-Term Debt to NOPAT		 0.00 0.00 -0.72 -0.76 -0.63 -0.73 -0.55 -0.34 -0.29 -1.20 -1.18
Altman Z-Score		 7.17 6.43 4.62 3.74 4.41 2.07 1.66 2.94 1.10 -0.33 -0.98
Noncontrolling Interest Sharing Ratio		 2.22% 2.40% 2.51% 2.00% 4.37% 5.05% 5.73% 0.00% 3.55% 0.00% 7.31%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.37 2.92 4.71 6.60 6.69 3.95 3.73 8.31 4.65 6.74 6.09
Quick Ratio		 3.25 2.72 4.44 6.32 6.45 3.83 3.46 8.03 4.52 6.60 5.92
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -151 -199 -63 -88 -148 -128 -306 -189 -170 -140 -66
Operating Cash Flow to CapEx		 -721.63% -210.13% -194.07% -115.95% -44.58% -40.57% -171.64% -271.10% -798.80% -564.93% -1,946.14%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -22.07 -17.48 -28.61 -24.31 -57.00 -26.08 -33.41 -9.54 -3.06
Operating Cash Flow to Interest Expense		 0.00 0.00 -26.51 -6.26 -4.03 -4.93 -21.96 -12.75 -22.66 -9.37 -6.76
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -40.16 -11.66 -13.06 -17.07 -34.75 -17.46 -25.49 -11.03 -7.10
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.34 0.35 0.36 0.34 0.33 0.33 0.24 0.04 0.02 0.00 0.00
Accounts Receivable Turnover		 549.31 41.70 14.02 7.71 344.84 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.18 3.06 2.79 2.27 1.69 1.20 0.76 0.13 0.06 0.01 0.01
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.66 8.75 26.04 47.33 1.06 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.66 8.75 26.04 47.33 1.06 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -108 -64 -142 -15 -33 -12 69 86 14 14 22
Invested Capital Turnover		 -1.58 -1.81 -1.76 -3.29 -3.64 -6.35 -4.97 1.00 -2.16 2.89 0.06
Increase / (Decrease) in Invested Capital		 100 141 33 137 76 52 210 101 47 26 -47
Enterprise Value (EV)		 3,161 3,036 3,781 2,290 3,415 2,597 3,188 3,146 2,912 2,237 2,309
Market Capitalization		 3,723 3,498 4,300 2,751 3,812 2,880 3,280 3,543 3,228 2,408 2,339
Book Value per Share		 $4.29 $3.77 $3.56 $4.12 $3.41 $2.53 $1.49 $3.90 $2.66 $1.49 $0.42
Tangible Book Value per Share		 $4.18 $3.65 $3.45 $4.02 $3.31 $2.44 $1.40 $3.83 $2.59 $1.42 $0.36
Total Capital		 474 418 476 545 462 392 289 609 451 695 575
Total Debt		 0.00 0.00 79 80 80 105 115 114 112 504 519
Total Long-Term Debt		 0.00 0.00 79 80 80 105 115 114 112 504 517
Net Debt		 -582 -482 -538 -480 -415 -299 -105 -409 -325 -177 -34
Capital Expenditures (CapEx)		 9.54 33 39 27 47 64 69 34 14 24 7.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -112 -110 -49 6.65 -52 -93 -46 -47 -83 -89 -75
Debt-free Net Working Capital (DFNWC)		 304 266 453 488 400 311 174 476 353 592 478
Net Working Capital (NWC)		 304 266 453 488 400 311 174 476 353 592 477
Net Nonoperating Expense (NNE)		 21 27 12 0.49 32 35 40 39 51 60 62
Net Nonoperating Obligations (NNO)		 -582 -482 -538 -480 -415 -299 -105 -409 -325 -177 -34
Total Depreciation and Amortization (D&A)		 4.28 3.56 3.38 1.90 2.33 2.87 3.43 6.26 12 -6.11 -0.47
Debt-free, Cash-free Net Working Capital to Revenue		 -44.94% -45.20% -17.55% 2.44% -20.20% -38.47% -25.37% -131.48% -424.08% -2,496.71% -2,981.28%
Debt-free Net Working Capital to Revenue		 121.70% 109.55% 162.75% 178.76% 156.10% 129.19% 95.84% 1,343.20% 1,798.39% 16,679.89% 19,136.12%
Net Working Capital to Revenue		 121.70% 109.55% 162.75% 178.76% 156.10% 129.19% 95.84% 1,343.20% 1,798.39% 16,679.89% 19,071.12%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.68) ($0.81) ($0.39) $0.46 ($0.96) ($1.03) ($1.24) ($1.02) ($1.38) ($1.36) ($1.39)
Adjusted Weighted Average Basic Shares Outstanding		 105.75M 105.43M 106.04M 106.76M 107.00M 106.75M 107.42M 123.29M 124.20M 119.78M 124.85M
Adjusted Diluted Earnings per Share		 ($0.68) ($0.80) ($0.39) $0.45 ($0.96) ($1.02) ($1.24) ($1.02) ($1.38) ($1.36) ($1.39)
Adjusted Weighted Average Diluted Shares Outstanding		 105.75M 105.43M 106.04M 108.14M 107.00M 106.75M 107.42M 123.29M 124.20M 119.78M 124.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 105.85M 106.01M 108.31M 106.90M 107.19M 107.43M 123.90M 124.20M 124.32M 124.43M 126.10M
Normalized Net Operating Profit after Tax (NOPAT)		 -51 -59 -29 34 -72 -76 -96 -88 -123 -114 -113
Normalized NOPAT Margin		 -157.46% -185.85% -47.16% 23.05% -454.29% -471.09% -2,691.68% 0.00% 0.00% 0.00% -4,519.54%
Pre Tax Income Margin		 -222.28% -260.20% -66.82% 32.60% -653.29% -677.08% -3,905.63% 0.00% 0.00% 0.00% -7,004.60%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -14.61 9.53 -19.85 -20.45 -25.36 -17.39 -34.43 -11.29 -7.44
NOPAT to Interest Expense		 0.00 0.00 -10.35 9.52 -13.94 -14.41 -17.81 -12.19 -24.20 -7.75 -5.22
EBIT Less CapEx to Interest Expense		 0.00 0.00 -28.27 4.12 -28.89 -32.60 -38.16 -22.10 -37.27 -12.95 -7.79
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -24.01 4.12 -22.97 -26.56 -30.60 -16.90 -27.04 -9.41 -5.57
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Arrowhead Pharmaceuticals' Financials

When does Arrowhead Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Arrowhead Pharmaceuticals' fiscal year ends in September. Their fiscal year 2024 ended on September 30, 2024.

How has Arrowhead Pharmaceuticals' net income changed over the last 10 years?

Arrowhead Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$609.69 million in 2024, rising from -$58.73 million in 2014. The previous period was -$209.28 million in 2023.

What is Arrowhead Pharmaceuticals's operating income?
Arrowhead Pharmaceuticals's total operating income in 2024 was -$601.08 million, based on the following breakdown:
  • Total Gross Profit: $3.55 million
  • Total Operating Expenses: $604.63 million
How has Arrowhead Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Arrowhead Pharmaceuticals' total revenue changed from $175 thousand in 2014 to $3.55 million in 2024, a change of 1,929.1%.

How much debt does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals' total liabilities were at $948.74 million at the end of 2024, a 98.3% increase from 2023, and a 5,536.7% increase since 2014.

How much cash does Arrowhead Pharmaceuticals have?

In the past 10 years, Arrowhead Pharmaceuticals' cash and equivalents has ranged from $24.84 million in 2017 to $221.80 million in 2019, and is currently $102.69 million as of their latest financial filing in 2024.

How has Arrowhead Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Arrowhead Pharmaceuticals' book value per share changed from 3.15 in 2014 to 1.49 in 2024, a change of -52.6%.

Remove Ads

Related Companies

This page (NASDAQ:ARWR) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners
Two Unmistakable Patterns Return…
The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...
Golden Portfolio | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Is it CRAZY to still want reliable profits, despite this market?
Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...
Brownstone Research | Sponsored
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...
Weiss Ratings | Sponsored
Tariffs. Volatility. Fear. Here’s the Plan.
Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...
Investors Alley | Sponsored
This story is about to go viral
This Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...
Stansberry Research | Sponsored
How War with China Could Start in 128 Days
The clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...
Behind the Markets | Sponsored